Yüklüyor......
Preclinical Development of CD38-Targeted [(89)Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Multiple myeloma (MM) is a plasma B-cell hematologic cancer that causes significant skeletal morbidity. Despite improvements in survival, heterogeneity in response remains a major challenge in MM. Cluster of differentiation 38 (CD38) is a type II transmembrane glycoprotein overexpressed in myeloma c...
Kaydedildi:
| Yayımlandı: | J Nucl Med |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Society of Nuclear Medicine
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5807532/ https://ncbi.nlm.nih.gov/pubmed/29025987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.117.196063 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|